79 related articles for article (PubMed ID: 8176939)
1. The synergistic antitumor effect of recombinant interleukin-1 and low-dose of cyclophosphamide in tumor-bearing mice.
Harada T; Kan N; Ichinose Y; Moriguchi Y; Li L; Sugie T; Okino T; Imamura M
J Surg Oncol; 1994 May; 56(1):39-45. PubMed ID: 8176939
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice.
Harada T; Kan N; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Ohgaki K; Imamura M
Biotherapy; 1993-1994; 7(2):91-9. PubMed ID: 7803195
[TBL] [Abstract][Full Text] [Related]
3. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
[TBL] [Abstract][Full Text] [Related]
4. Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide.
Li L; Okino T; Kan N; Yamasaki S; Ichinose Y; Sugie T; Kanaoka S; Imamura M
Biotherapy; 1998; 11(4):223-8. PubMed ID: 9950097
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Usui N; Matsushima K; Pilaro AM; Longo DL; Wiltrout RH
Biotherapy; 1996; 9(4):199-208. PubMed ID: 9012539
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
7. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
Nakamura S; Kashimoto S; Kajikawa F; Nakata K
Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
[TBL] [Abstract][Full Text] [Related]
8. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
[TBL] [Abstract][Full Text] [Related]
9. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
10. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
Shanahan TC; Ceglowski WS; Havas HF
Cancer Res; 1985 Dec; 45(12 Pt 1):6463-70. PubMed ID: 2866030
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha.
Ohkura M; Fuchimoto S; Orita K
Jpn J Cancer Res; 1990 Oct; 81(10):1026-31. PubMed ID: 2121675
[TBL] [Abstract][Full Text] [Related]
13. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
14. The induction of specific antitumor immunity by in vivo treatment with interleukin-1 and sonicated tumor extract in a murine model.
Harada T; Kan N; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Ohgaki K; Imamura M
Surg Today; 1994; 24(6):561-3. PubMed ID: 7919743
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
Cao X; Li Q; Ju DW; Wang Q; Tao Q; Wang J
Transplantation; 1999 May; 67(9):1242-50. PubMed ID: 10342316
[TBL] [Abstract][Full Text] [Related]
17. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
Tanida S; Uchida H; Taniguchi K; Nomoto K
Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Reissmann T; Hilgard P; Voegeli R; Zeller J
J Cancer Res Clin Oncol; 1989; 115(6):525-30. PubMed ID: 2606928
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of active specific immunotherapy using interferon-gamma-gene-transduced tumor cells in a murine tumor model.
Moriguchi Y; Kan N; Okino T; Teramura Y; Yamasaki S; Ichinose Y; Li L; Sugie T; Kuribayashi K; Watanabe Y; Imamura M
Surg Today; 1997; 27(6):571-3. PubMed ID: 9306555
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
Li LH; Wallace TL; Richard KA; Tracey DE
Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
